Introduction {#s1}
============

Common genetic variants associated with type 2 diabetes are more likely to be associated with insulin secretion than insulin resistance ([@B1]). Studies of genetic variation and insulin secretion have been largely limited to fasting glucose-- or oral glucose tolerance test (OGTT)--based measures of β-cell function and insulin secretion ([@B2],[@B3]). Oral-based measures of insulin secretion do not distinguish between mechanisms involving gut hormone signaling, e.g., incretin pathways, and mechanisms intrinsic to islet cell function or mass.

Compared with OGTT-based measures, intravenous-based measures provide a more accurate measure of first-phase insulin secretion, with initial release of insulin peaking in the first 5--10 min following glucose stimulation. Intravenous measures include the intravenous glucose tolerance test (IVGTT) and hyperglycemic clamp. Family studies have shown that first-phase insulin response as measured by IVGTT is one of the most highly heritable glycemic measures ([@B4]--[@B9]), but genetic studies of intravenous-based measures of insulin secretion have examined limited numbers of variants or been performed in single studies ([@B8],[@B10]--[@B14]), with the exception of a recent meta-analysis performed in Hispanic Americans ([@B15]).

Two studies have examined the effects of known type 2 diabetes variants in large meta-analyses of studies with OGTT data. A study of 23,443 individuals with OGTT-based measures of insulin secretion and insulin resistance, with a subset of 4,180 individuals with clamp-based measures of insulin resistance, examined 36 known type 2 diabetes variants ([@B2]). This study classified 16 variants into groups: nine were labeled as "β-cell," two as "hyperglycemia," four as "insulin resistance," and one as "insulin processing" (based on proinsulin measures). This analysis left 20 variants as "unclassified," which may include those that do not operate through these mechanisms as defined or may reflect a lack of power to distinguish mechanisms when the type 2 diabetes risk effect is relatively weak. A second study performed a six-study genome-wide association study (GWAS) meta-analysis of OGTT-based measures of insulin secretion, including the corrected insulin response (CIR; insulin response corrected to glucose at 30 min during an OGTT) ([@B3]). This study provided genome-wide data from 10,831 individuals and identified a signal in *GRB10* but otherwise did not identify any variants not previously identified as type 2 diabetes variants.

Here we performed a meta-analysis--based GWAS of intravenous-based measures of glucose-stimulated insulin secretion. We used several measures of first-phase insulin secretion with two aims: first, to refine the underlying physiology of known type 2 diabetes and glycemic trait variants, and second, to identify novel variants associated with first-phase insulin secretion. Our study provides an advance to previous studies in several ways. First, it is the largest GWAS meta-analysis of intravenous-based measures of glucose-stimulated insulin secretion. Second, we used imputation from the 1000 Genomes Project to capture a wider range of genetic variation than previous GWAS of glycemic traits. Third, we focused on characterizing the most recent lists of known type 2 diabetes and glycemic trait variants. Using more than 5,500 individuals with intravenous measures of first-phase insulin secretion, we show that most variants previously associated with insulin secretion, as measured by OGTT, operate through a primary islet cell--based mechanism, and we provide new insight into the mechanisms of several variants where previous data had been unclear.

Research Design and Methods {#s2}
===========================

Study Samples {#s3}
-------------

The meta-analysis consisted of a total of 10 studies and a maximum of 5,567 individuals, with the full number available depending on the phenotype. These studies represented several different ethnic groups, with 3 studies of 2,346 Hispanic (Insulin Resistance Atherosclerosis Family Study \[IRASFS\] \[[@B16]\], Troglitazone In the Prevention Of Diabetes \[TRIPOD\] \[[@B17]\], BetaGene \[[@B18]\]), 6 studies of 2,900 individuals of European ancestry (European Network on Functional Genomics of Type 2 Diabetes \[EUGENE2\] \[[@B19]\], Relationship between Insulin Sensitivity and Cardiovascular Disease \[RISC\] \[[@B20]\], hyperglycemic clamp cohorts \[HCC\] \[[@B13]\], YOUTH 92 \[[@B21]\], FAMILY \[[@B21]\], and Finland-United States Investigation of NIDDM Genetics \[FUSION\] \[[@B22]\]), and 1 study of 332 Pima Indians ([@B23]). All studies were genotyped with a GWAS chip except the 413 HCC participants and a subset of 328 of 554 individuals from the FUSION study who were typed with the MetaboChip ([@B24]). Full descriptive characteristics, study design, sample size, sample quality control, and intravenous measurement techniques for the included studies are provided in [Supplementary Tables 1--3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1452/-/DC1). All participants provided written informed consent, and the studies were approved by the respective local research ethics committees or institutional review boards.

Phenotypes {#s4}
----------

The 10 studies each used a version of the IVGTT test. FUSION, YOUTH 92, FAMILY, and TRIPOD used tolbutamide-modified IVGTTs, and IRASFS and BetaGene used insulin-modified IVGTTs. In the RISC study, the IVGTT was conducted at the end of an isoglycemic clamp as previously reported ([@B25]). In the HCC study, participants underwent a hyperglycemic clamp after an overnight fast. After the priming glucose bolus, blood glucose was measured at 2- to 2.5-min intervals and kept constant at 10 mmol/L for at least 2 hours via continuous variable glucose infusions ([@B13]). The EUGENE2 study used a 0.3 g/kg body weight glucose bolus and the Pima Indian study used a 25-g glucose bolus.

### Peak Insulin Response {#s5}

Peak insulin response was measured as peak insulin minus baseline insulin. The peak insulin time point was determined for each study, according to the time point having the highest average insulin value across all individuals.

### Acute Insulin Response {#s6}

Acute insulin response (AIR) was measured as the incremental area under the insulin curve during the first 10 min, or if a measure at 10 min was not available, during the first 8 min, using the trapezium equation ([@B26]), with a minimum of insulin values at 0, 2, 4, 6, and 8 min during the IVGTT. Incremental insulin was calculated by subtracting the fasting insulin level.

### Insulin Secretion Rate {#s7}

Insulin secretion rate (ISR) was estimated from measured serum C-peptide concentrations at 0,2,4,6,8 (RISC) and 0, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 19 (FAMILY) min, using the ISEC software ([@B27],[@B28]), which calculates the secretion rate based on predefined C-peptide kinetic parameters from each individual's weight, height, age, sex, and clinical status (glucose tolerance and obesity status) determined in a population-based study ([@B29],[@B30]). ISR provides an estimate of the rate of insulin secretion prior to hepatic insulin clearance.

### Insulin Sensitivity {#s8}

We used the MINMOD software ([@B31]) to calculate insulin sensitivity or a method suitable to the study (e.g., for hyperglycemic clamps, see 't Hart et al. \[[@B13]\]).

### Disposition Index {#s9}

Disposition index (DI) was calculated as the product of AIR, and insulin sensitivity index was calculated using the MINMOD software ([@B31]). DI differs from peak insulin response and AIR because it is not a pure test of insulin secretion but takes into account the level of background insulin resistance.

### OGTT Measures of Insulin Secretion as a Comparison {#s10}

CIR was based on OGTT. To compare IVGTT-based results to OGTT-based results, we calculated the CIR in a subset of 2,523 individuals from five of our studies. Calculation was the same as that used and described by Prokopenko et al. ([@B3]): CIR = (100 × insulin at 30 min)/(glucose at 30 min × \[glucose at 30 min -- 3.89\]).

Genotyping and Imputation {#s11}
-------------------------

### Genotyping and Imputation Within Studies {#s12}

Details on the genotyping platform used and genotype quality control procedures used for each study are presented in [Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1452/-/DC1). All GWAS cohorts were genotyped using commercially available Affymetrix (Santa Clara, CA) or Illumina (San Diego, CA) genotyping arrays. To facilitate meta-analyses for each trait, studies performed genotype imputation using MACH ([@B32]), MINIMAC ([@B33]), or IMPUTE ([@B34]) to impute up to a common set of variants. All studies (except the Pima study) imputed up to ∼39 million single nucleotide polymorphisms (SNPs) and indels from 2,184 haplotypes available from the 1000 Genomes Project Phase 1, version 3 ([@B35]). Because of the relative difference in ancestry between the Pima cohort and the samples within the 1000 Genomes reference panel, imputation in Pima was based on 532 haplotypes derived from whole-genome sequencing efforts within the Pima study.

### MetaboChip Genotyping {#s13}

Additional studies genotyped on the Illumina MetaboChip without subsequent imputation but with available phenotype data were also incorporated into the meta-analysis. Details of these studies can be found in [Supplementary Tables 1--3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1452/-/DC1).

Statistical Analysis {#s14}
--------------------

### Phenotype Transformations {#s15}

Each trait was adjusted for age, sex, and study-specific covariates as necessary ([Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1452/-/DC1)) by adding them to a regression model and using the residuals as the phenotype. We then inverse normalized this residualized phenotype to create a normal distribution. This process is important to reduce false-positive results when testing thousands of rarer variants. Analyses were repeated adjusting for BMI and insulin sensitivity. To account for population stratification, studies also adjusted for principal components or if running association testing outside of a linear mixed-model framework.

### Association Analysis {#s16}

Additive association analysis for each trait was carried out using MACH2QTL ([@B32]), SOLAR (for IRASFS), or linear mixed models, as implemented in EMMAX ([@B36]), GEMMA ([@B37]), or QTassoc ([@B38]) ([Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1452/-/DC1)). For each trait and adjustment combination, we performed a fixed-effects meta-analysis based on standard errors, as implemented in METAL (<http://csg.sph.umich.edu/abecasis/Metal>). We applied a variant minor allele count filter of \>5 and genomic control correction to the input files prior to meta-analysis. Variants with a meta-analysis *P* \< 5 × 10^−8^ were considered to be genome-wide significant. All genome-wide statistics are available on our website (<http://www.t2diabetesgenes.org/data/>).

Selection of Known Variants and Previous Traits {#s17}
-----------------------------------------------

### Type 2 Diabetes {#s18}

We selected 76 variants identified by GWAS as associated with type 2 diabetes. For European studies, these were based on a GWAS + MetaboChip meta-analysis of 34,840 case and 114,981 control subjects ([@B39]), and for non-Europeans, this included variants at GWAS significance across a *trans*-ethnic study meta-analysis of 26,488 case and 83,964 control subjects ([@B40]).

### Glycemic and Insulin-Related Traits {#s19}

We selected variants representing 65 signals listed in the supplementary or main tables of Prokopenko et al. ([@B3]) as associated with a glycemic or insulin-related trait, including fasting glucose, fasting insulin, 2-h insulin, HbA~1c~, and proinsulin. We also selected an additional five variants associated with fasting glycemic traits identified by an earlier meta-analysis that fell 250 kb outside of the 65 signals ([@B41]).

Results {#s20}
=======

Several Variants Are Associated With Intravenous-Based Measures of First-Phase Insulin Secretion at Genome-Wide Significance, Including *MTNR1B* and *CDKAL1* {#s21}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

Results are represented in [Tables 1](#T1){ref-type="table"}--[5](#T5){ref-type="table"} and [Figs. 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, and [4](#F4){ref-type="fig"}. The two strongest association signals represented known type 2 diabetes loci, those in or near *MTNR1B* and *CDKAL1* ([Table 1](#T1){ref-type="table"}). The known signal at *MTNR1B* was associated with peak insulin response (*P* = 1.3 × 10^−24^), AIR (*P* = 3.7 × 10^−21^), and DI (*P* = 3.3 ×× 10^−17^), and *CDKAL1* with peak insulin response (*P* = 1.5 × 10^−12^) and AIR (*P* = 1.5 × 10^−9^). The peak insulin response and AIR results were very similar after adjusting for BMI and/or SI ([Supplementary Table 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1452/-/DC1)). In addition, we identified a few novel genome-wide associations that require further validation and replication; these associations were either rare variants (*REG3G*), only present in a specific ethnic group (*CHST1*), or sensitive to covariates used (*BLVRA/MRPS24*) ([Supplementary Table 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1452/-/DC1)). We tested these novel variants for an association with type 2 diabetes in the DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) GWAS ([@B40]), but none of the SNPs were associated with type 2 diabetes at *P* \< 0.05.

###### 

Type 2 diabetes risk alleles associated with lower first-phase insulin response, AIR, or peak insulin response (*P* \< 0.05), from a total of 76 analyzed

  Locus                  OGTT/fasting[\*](#t1n1){ref-type="table-fn"}   Lead SNP         Chr      Position[‡](#t1n2){ref-type="table-fn"}   Risk allele   Peak insulin response   AIR                                                 
  ---------------------- ---------------------------------------------- ---------------- -------- ----------------------------------------- ------------- ----------------------- ----------- -------------- ------------ ----------- --------------
  ***MTNR1B***           **HG (1,2)**                                   **rs10830963**   **11**   **92,708,710**                            **G**         **−0.235**              **0.023**   **1.34E-24**   **−0.218**   **0.023**   **3.65E-21**
  ***CDKAL1***           **BC (1,2)**                                   **rs7756992**    **6**    **20,679,709**                            **G**         **−0.152**              **0.022**   **1.50E-12**   **−0.131**   **0.022**   **1.45E-09**
  ***HNF1A***            **UC (1,2)**                                   **rs12427353**   **12**   **121,426,901**                           **G**         **−0.141**              **0.029**   **1.07E-06**   **−0.136**   **0.029**   **3.15E-06**
  ***IGF2BP2***          **UC**                                         **rs4402960**    **3**    **185,511,687**                           **T**         **−0.101**              **0.022**   **4.90E-06**   **−0.091**   **0.022**   **4.65E-05**
  ***TCF7L2***           **BC (1)**                                     **rs7903146**    **10**   **114,758,349**                           **T**         **−0.105**              **0.024**   **7.39E-06**   **−0.103**   **0.024**   **1.43E-05**
  ***ARAP1 (CENTD2)***   **PROINS (2)**                                 **rs1552224**    **11**   **72,433,098**                            **A**         **−0.128**              **0.030**   **1.92E-05**   **−0.140**   **0.030**   **3.54E-06**
  ***SLC30A8***          **BC (1)**                                     **rs3802177**    **8**    **118,185,025**                           **G**         **−0.089**              **0.022**   **5.88E-05**   **−0.090**   **0.022**   **5.94E-05**
  ***ADCY5***            **BC (2)**                                     **rs11717195**   **3**    **123,082,398**                           **T**         **−0.092**              **0.023**   **8.43E-05**   −0.078       0.023       8.33E-04
  ***KCNQ1***            **UC (1,2)**                                   **rs163184**     **11**   **2,847,069**                             **G**         **−0.075**              **0.020**   **1.52E-04**   **−0.082**   **0.020**   **3.73E-05**
  *C2CD4A*               N/A (1,2)                                      rs7163757        15       62,391,608                                C             −0.072                  0.022       8.05E-04       −0.071       0.022       9.34E-04
  *HHEX/IDE*             BC (1)                                         rs1111875        10       94,462,882                                C             −0.061                  0.020       0.003          −0.058       0.020       0.005
  ***CDKN2A/B***         **BC (1)**                                     **rs10811661**   **9**    **22,134,094**                            **T**         −0.087                  0.029       0.003          **−0.102**   **0.030**   **6.00E-04**
  *FAF1*                 N/A                                            rs17106184       1        50,909,985                                G             −0.104                  0.039       0.008          −0.091       0.039       0.020
  *PTPRD*                N/A (1)                                        rs17584499       9        8,879,118                                 T             −0.063                  0.027       0.020          −0.062       0.027       0.023
  *PROX1*                BC                                             rs2075423        1        214,154,719                               G             −0.050                  0.022       0.021          −0.060       0.022       0.006
  *AP3S2*                N/A (2)                                        rs2028299        15       90,374,257                                C             −0.057                  0.026       0.026          −0.052       0.026       0.045
  *HNF1B*                UC (1)                                         rs4430796        17       36,098,040                                G             −0.045                  0.022       0.039          −0.066       0.022       0.003
  *MAEA*                 N/A (2)                                        rs6815464        4        1,309,901                                 C             −0.059                  0.031       0.060          −0.063       0.031       0.043
  *KCNK16*               N/A                                            rs1535500        6        39,284,050                                T             −0.041                  0.022       0.060          −0.045       0.022       0.041
  *DGKB*                 BC                                             rs17168486       7        14,898,282                                T             −0.044                  0.024       0.061          −0.050       0.024       0.034
  *LPP*                  N/A                                            rs6808574        3        187,740,523                               C             −0.039                  0.023       0.090          −0.048       0.023       0.040

β represents per allele effects in SD. Associations reaching Bonferroni equivalents of *P* \< 0.05 are in bold typeface. Chr, chromosome.

\*Association (*P* \< 0.05) with OGTT-based measure of insulin secretion or fasting glucose, as reported by: 1, Prokopenko et al. ([@B3]) (CIR) and 2, this study (CIR~BMI\ +\ SI\ adjusted~), as classified by Dimas et al. ([@B2]): HG, hyperglycemia-reduced β-cell function after glucose stimulation; BC, defective β-cell function; PROINS, decreased proinsulin; UC, unclassified; N/A, not available.

‡Base pair position build-37.

![IVGTT (peak insulin response)-based first-phase insulin secretion vs. OGTT-based insulin secretion (CIR) for known type 2 diabetes variants. Data are SD. Orange circles, SNP associated with both peak insulin response and CIR (*P* \< 0.05); green circles, SNP associated with peak insulin response (*P* \< 0.05); blue circles, SNP associated with CIR (*P* \< 0.05); yellow circles; SNP not associated with either trait (*P* \> 0.05). ISI, insulin sensitivity index.](db161452f1){#F1}

![ISR- vs. OGTT-based insulin secretion (CIR) for known type 2 diabetes variants. Data are SD. Orange circles, SNP associated with both ISR and CIR (*P* \< 0.05); green circles, SNP associated with ISR (*P* \< 0.05); blue circles, SNP associated with CIR (*P* \< 0.05); yellow circles, SNP not associated with either trait (*P* \> 0.05). ISI, insulin sensitivity index.](db161452f2){#F2}

![IVGTT (peak insulin response)-based first-phase insulin secretion vs. type 2 diabetes risk (OR) for known type 2 diabetes variants. The *y*-axis data are SD. Type 2 diabetes ORs are from Morris et al. ([@B39]), and some were reported from previous studies of East Asians ([@B59],[@B60]). Orange circles, SNP associated with both peak insulin response and type 2 diabetes risk (*P* \< 0.05); green circles, SNP associated with peak insulin response (*P* \< 0.05); blue circles, SNP associated with type 2 diabetes risk (*P* \< 0.05); yellow circles, SNP not associated with either trait (*P* \> 0.05). T2D, type 2 diabetes.](db161452f3){#F3}

![ISR vs. type 2 diabetes risk for known type 2 diabetes variants. The *y*-axis data are SD. Orange circles, SNP associated with both ISR and type 2 diabetes risk (*P* \< 0.05); green circles, SNP associated with ISR (*P* \< 0.05); blue circles, SNP associated with type 2 diabetes risk (*P* \< 0.05); yellow circles, SNP not associated with either trait (*P* \> 0.05). T2D, type 2 diabetes.](db161452f4){#F4}

Twenty-one Known Type 2 Diabetes Risk Alleles Are Associated With Lower First-Phase Insulin Response {#s22}
----------------------------------------------------------------------------------------------------

Of 76 type 2 diabetes known risk alleles, 21 were associated (at *P* \< 0.05) with reduced first-phase insulin secretion as measured by peak insulin response or AIR (17 variants were associated with both peak insulin response and AIR at *P* \< 0.05) ([Table 1](#T1){ref-type="table"}). Peak insulin response and AIR associations tended to be very similar for all variants ([Table 1](#T1){ref-type="table"}). This number of risk alleles associated with reduced insulin secretion at *P* \< 0.05 is far more than the 2--3 expected by chance. Three additional type 2 diabetes risk alleles were associated with higher first-phase insulin response and are discussed below (*NOTCH2*, *PPARG*, and *GCC1*). Results were similar when adjusting for BMI and insulin sensitivity ([Supplementary Table 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1452/-/DC1)). These 21 variants included 10 previously classified as having a clear role in insulin secretion, 8 were previously classified as "β-cell," 1 as "hyperglycemia" (*MTNR1B*), and 1 as "insulin processing" (*ARAP1/STARD10*) ([@B2]). We did not detect any evidence that the variant previously labeled as "β-cell" in the *THADA* gene was associated with first-phase insulin response. We were not able to account for the potential parent of origin effect at THADA ([@B42]), but neither were the previous largest OGTT-based studies. Of the 11 other variants we detected, those in the *HNF1A*, *IGF2BP2*, and *KCNQ1* genes had previously been associated with at least one measure of insulin secretion or fasting glucose, and our data now strengthens the evidence that these variants increase type 2 diabetes risk through an insulin secretory mechanism, including lower first-phase insulin response. Our findings provide new evidence that type 2 diabetes variants in the loci labeled as in or near the *HNF1B*, *VPS13C/C2CD4A*, *FAF1*, *PTPRD*, *AP3S2*, *KCNK16*, *MAEA*, and *LPP* genes alter type 2 diabetes risk through mechanisms that include first-phase insulin secretion. Although none of these 8 reached Bonferroni-corrected levels of significance, we would only expect 2--3 of 76 type 2 diabetes risk alleles to be associated with lower insulin secretion at *P* \< 0.05, suggesting most of these 8 variants operate through insulin secretion mechanisms ([Table 1](#T1){ref-type="table"}).

Six Variants Associated With Higher Fasting Glucose but Not Type 2 Diabetes Are Associated With Lower First-Phase Insulin Secretion {#s23}
-----------------------------------------------------------------------------------------------------------------------------------

We next examined 70 known variants associated with intermediate glycemic traits. These traits consisted of those analyzed by the Meta-Analyses of Glucose and Insulin-Related Traits Consortium (MAGIC) and included fasting glucose and insulin, proinsulin, HbA~1c~, and 2-h post-OGTT glucose levels. These variants partially overlap those associated with type 2 diabetes. We identified 6 variants not in the type 2 diabetes list where the fasting glucose--raising allele was associated with first-phase insulin secretion before ([Table 2](#T2){ref-type="table"}) and after correcting for BMI and insulin sensitivity ([Supplementary Table 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1452/-/DC1)). Fasting glucose--raising alleles in or near the *PDX1*, *DNLZ*, *CRY2*, *GLIS3*, *PROX1*, and *ADRA2A* genes were associated with lower first-phase insulin secretion at *P* \< 0.05. We next examined published data from the DIAGRAM consortium to establish whether or not these alleles were associated with type 2 diabetes but had not reached genome-wide significance---only the allele at *PDX1* was not nominally associated with type 2 diabetes (*P* \> 0.05) in Morris et al. ([@B39]). All five of the other alleles associated with higher fasting glucose and lower first-phase insulin were associated with a higher risk of type 2 diabetes with *P* values of 0.03 (*CRY2*, odds ratio \[OR\] 1.03), 0.001 (*ADRA2A*, OR 1.06), 0.0001 (*GLIS3*, OR 1.04), 0.0001 (*DNLZ*, OR 1.06), and 1 × 10^−7^ (*PROX1*, OR 1.06) ([@B39]).

###### 

Fasting glucose--raising alleles associated with lower first-phase insulin response but not identified as a type 2 diabetes risk allele

  Locus        Lead SNP         Chr      Position[†](#t2n1){ref-type="table-fn"}   Effect allele   Peak insulin response   AIR                                                 
  ------------ ---------------- -------- ----------------------------------------- --------------- ----------------------- ----------- -------------- ------------ ----------- --------------
  ***PDX1***   **rs11619319**   **13**   **28,487,599**                            **G**           **−0.106**              **0.023**   **2.54E-06**   **−0.115**   **0.023**   **3.74E-07**
  ***DNLZ***   **rs3829109**    **9**    **139,256,766**                           **G**           **−0.088**              **0.022**   **5.77E-05**   **−0.089**   **0.022**   **4.83E-05**
  *CRY2*       rs11607883       11       45,839,709                                G               −0.047                  0.020       0.017          −0.055       0.020       0.005
  *GLIS3*      rs10814916       9        4,293,150                                 C               −0.044                  0.020       0.029          −0.046       0.020       0.023
  *PROX1*      rs340874         1        214,159,256                               C               −0.041                  0.020       0.039          −0.056       0.020       0.006
  *ADRA2A*     rs11195502       10       113,039,667                               C               −0.069                  0.035       0.052          −0.079       0.036       0.026

β represents per allele effects in SD. Associations reaching Bonferroni equivalents of *P* \< 0.05 are in bold typeface. Chr, chromosome.

†Base pair position build-37.

Ten Known Type 2 Diabetes or Glycemic Trait Alleles Are Associated With Lower ISR {#s24}
---------------------------------------------------------------------------------

For a subset of 1,268 individuals without diabetes, we had a measure of ISR by C-peptide deconvolution ([@B27],[@B30]). For 10 known variants, the type 2 diabetes or glycemic trait risk allele was associated with lower ISR at *P* \< 0.05. These analyses highlighted 2 variants that had no clear underlying physiological profile based on previous OGTT data or our own peak insulin response or AIR analyses---those in *WFS1* and *TMPRSS6* ([Table 3](#T3){ref-type="table"}). Of these 10 variants previously associated with a glycemic trait and associated with ISR in our study, 2 were not known type 2 diabetes variants---those in *TMPRSS6* (HbA~1c~-raising allele associated with lower ISR) and *PDX1* (fasting glucose--raising allele associated with lower ISR). The *TMPRSS6* allele, like the *PDX1* allele, was not nominally associated with type 2 diabetes in the DIAGRAM study (*P* \> 0.05).

###### 

Known type 2 diabetes and glycemic trait variants associated with ISR

  Locus            Trait        Classification[†](#t3n1){ref-type="table-fn"}   Association pattern[‡](#t3n2){ref-type="table-fn"}   Lead SNP         Chr      Position[\|\|](#t3n3){ref-type="table-fn"}   Risk allele   ISR                      
  ---------------- ------------ ----------------------------------------------- ---------------------------------------------------- ---------------- -------- -------------------------------------------- ------------- ------------ ----------- --------------
  ***MTNR1B***     **T2D/FG**   **HG**                                          **1,2,3,4**                                          **rs10830963**   **11**   **92,708,710**                               **G**         **−0.232**   **0.043**   **9.01E-08**
  ***CDKAL1***     **T2D/FG**   **BC**                                          **1,2,3,4**                                          **rs7756992**    **6**    **20,679,709**                               **G**         **−0.232**   **0.045**   **1.91E-07**
  ***CDKN2A/B***   **T2D/FG**   **BC**                                          **1,2,3**                                            **rs10811661**   **9**    **22,134,094**                               **T**         **−0.224**   **0.054**   **3.46E-05**
  *WFS1*           T2D          UC                                              ---                                                  rs4458523        4        6,289,986                                    G             −0.124       0.041       0.003
  *SLC30A8*        T2D/FG       BC                                              1,2,3                                                rs3802177        8        118,185,025                                  G             −0.122       0.044       0.006
  *TMPRSS6*        HbA~1c~      N/A                                             ---                                                  rs855791         22       37,462,936                                   A             −0.114       0.042       0.006
  *PDX1*           FG           N/A                                             1,2,4                                                rs11619319       13       28,487,599                                   G             −0.129       0.049       0.008
  *ANK1*           T2D          N/A                                             3                                                    rs516946         8        41,519,248                                   C             −0.113       0.048       0.018
  *HHEX/IDE*       T2D          BC                                              1,2,3                                                rs1111875        10       94,462,882                                   C             −0.086       0.041       0.037
  *IGF2BP2*        T2D/FG       UC                                              1,2                                                  rs4402960        3        185,511,687                                  T             −0.091       0.044       0.037

*N* = 1,268. β represents per allele effects in SD. Associations reaching Bonferroni equivalents of *P* \< 0.05 are in bold typeface. Chr, chromosome; FG, fasting glucose; T2D, type 2 diabetes.

†Classification by Dimas et al. ([@B2]): HG, hyperglycemic; BC, β-cell; UC, unclassified; N/A, not available.

‡Code relating to significance of association across phenotypes and data sets: 1, associated at *P* \< 0.05 with peak insulin response in our data; 2, associated at *P* \< 0.05 with AIR in our data; 3, associated with CIR in Prokopenko et al. ([@B3]); 4, associated at *P* \< 0.05 with CIR~BMI\ +\ SI~ adjustment in our data.

\|\|Base pair position build-37.

Sixteen Variants Where the Type 2 Diabetes Risk Allele Is Apparently Paradoxically Associated With Higher Insulin Secretion or ISRs {#s25}
-----------------------------------------------------------------------------------------------------------------------------------

We identified 16 variants with apparently paradoxical effects on type 2 diabetes risk, glycemic traits, and first-phase insulin secretion or ISR. These included 3 (*PPARG*, *FTO, TET2*) with known primary effects on insulin resistance ([@B43]) or BMI and 3 (*ARAP1*, *PCSK1*, *MADD*) ([@B44]) with known primary effects on proinsulin. Although the effects on insulin secretion were similar when correcting for insulin resistance and BMI, the associations with DI tended to be weaker ([Tables 4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}).

###### 

Apparently paradoxical associations between known glycemic variants and first-phase insulin secretion

  Locus                                             Known trait[\*](#t4n1){ref-type="table-fn"}   Lead SNP     Chr   Position[‡](#t4n2){ref-type="table-fn"}   Effect allele   Peak insulin response   AIR         DI[¶](#t4n3){ref-type="table-fn"}                                                                        
  ------------------------------------------------- --------------------------------------------- ------------ ----- ----------------------------------------- --------------- ----------------------- ----------- ----------------------------------- -------------- ----------- ----------- -------------- -------------- -------------
  *G6PC2*                                           FG                                            rs560887     2     169,763,148                               C               **0.061**               **0.024**   **0.012**                           **6.70E-04**   **0.074**   **0.024**   **0.002**      **8.25E-05**   **1.1E-04**
  *GRB10*                                           FG                                            rs6943153    7     50,791,579                                T               0.069                   0.021       8.47E-04                            0.003          0.066       0.021       0.002          0.003          0.018
  *OR4S1*/*PTPRJ*[\#](#t4n4){ref-type="table-fn"}   FG                                            rs1483121    11    48,333,360                                G               0.114                   0.036       0.002                               0.001          0.111       0.036       0.002          0.002          0.033
  *MADD*                                            Fproinsulin                                   rs10501320   11    47,293,799                                G               0.084                   0.029       0.003                               **4.12E-04**   0.090       0.029       0.002          **4.82E-04**   0.252
  *PCSK1*                                           Fproinsulin                                   rs6235       5     95,728,898                                G               **0.096**               **0.025**   **1.09E-04**                        0.002          **0.104**   **0.025**   **2.98E-05**   **4.35E-04**   0.013
  *PPARG*                                           FI-adjBMI                                     rs17036328   3     12,390,484                                T               0.096                   0.029       9.42E-04                            0.012          **0.110**   **0.029**   **1.64E-04**   0.005          0.302
  *ARAP1*                                           Fproinsulin                                   rs11603334   11    72,432,985                                A               **0.128**               **0.030**   **1.96E-05**                        8.55E-04       **0.140**   **0.030**   **3.60E-06**   **7.45E-05**   0.027
  *FTO*                                             BMI                                           rs1421085    16    53,800,954                                C               0.038                   0.022       0.084                               0.688          0.048       0.022       0.031          0.951          0.253
  *GCC1*                                            T2D                                           rs6467136    7     127,164,958                               G               0.052                   0.022       0.015                               0.024          0.050       0.022       0.021          0.033          0.068
  *NOTCH2*                                          T2D                                           rs10923931   1     120,517,959                               T               0.066                   0.032       0.039                               0.057          0.053       0.032       0.1            0.212          0.272

β represents per allele effects in SD. Associations reaching Bonferroni equivalents of *P* \< 0.05 are in bold typeface. Chr, chromosome; FG, fasting glucose; FI-adjBMI, fasting insulin adjusted for BMI; Fproinsulin, fasting proinsulin; T2D, type 2 diabetes.

\*Trait previously associated with SNP.

‡Base pair position build-37.

\|\|*P* value after BMI + SI adjustment.

¶DI adjusted for BMI.

\#*PTPRJ* is the nearest nonolfactory receptor gene in the locus.

###### 

Apparently paradoxical associations between known glycemic variants and ISR

  Locus             Trait         Classification[†](#t5n1){ref-type="table-fn"}   Association pattern[‡](#t5n2){ref-type="table-fn"}   Lead SNP     Chr   Position[\|\|](#t5n4){ref-type="table-fn"}   Risk allele   ISR     DI                         
  ----------------- ------------- ----------------------------------------------- ---------------------------------------------------- ------------ ----- -------------------------------------------- ------------- ------- ------- ------- ---------- -------
  *GRB10*           FG            N/A                                             3                                                    rs6943153    7     50,791,579                                   T             0.143   0.045   0.001   8.25E-04   0.018
  *HMG20A*          T2D           N/A                                             ---                                                  rs7178572    15    77,747,190                                   G             0.136   0.043   0.001   0.002      0.969
  *OR4S1*/*PTPRJ*   FG            N/A                                             ---                                                  rs1483121    11    48,333,360                                   G             0.232   0.086   0.007   0.003      0.033
  *PCSK1*           Fproinsulin   N/A                                             ---                                                  rs6235       5     95,728,898                                   G             0.108   0.044   0.015   0.02       0.013
  *TMEM163*         T2D           N/A                                             2                                                    rs6723108    2     135,479,980                                  T             0.094   0.042   0.024   0.03       0.854
  *ADAMTS9*         T2D           UC                                              ---                                                  rs6795735    3     64,705,365                                   C             0.088   0.040   0.028   0.02       0.428
  *IKBKAP*          FG            N/A                                             ---                                                  rs16913693   9     111,680,359                                  T             0.246   0.117   0.036   0.05       0.404
  *KLHDC5*          T2D           N/A                                             ---                                                  rs10842994   12    27,965,150                                   C             0.104   0.050   0.038   0.04       0.291
  *TET2*            FI            N/A                                             ---                                                  rs9884482    4     106,081,636                                  C             0.082   0.041   0.048   0.03       0.788

β represents per allele effects in SD. Chr, chromosome; FG, fasting glucose; FI; fasting insulin; Fproinsulin, fasting proinsulin; T2D, type 2 diabetes.

†Classification by Dimas et al. ([@B2]): UC, unclassified; N/A, not available.

‡Code relating to significance of association across phenotypes and data sets: 2, associated at *P* \< 0.05 with AIR in our data; 3, associated with CIR in Prokopenko et al. ([@B3]).

\|\|Base pair position build-37.

\#*P* value after ISR adjustment for BMI.

Discussion {#s26}
==========

By performing a large GWAS of first-phase IVGTT-based insulin secretion, we provide new insights into the likely mechanisms by which some of the known type 2 diabetes and glycemic trait variants affect glucose homeostasis. Our results complement those from OGTT-derived measures of insulin secretion and emphasize the need to consider first-phase, second-phase, and C-peptide--derived measures of insulin secretion and insulin resistance when considering the likely function of type 2 diabetes--associated alleles. We provide details of 178 previously described associations in [Supplementary Table 8](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1452/-/DC1). We did not identify any robust associations between new variants and IVGTT-based measures of insulin secretion and so we focus this discussion on the known variants. The lack of novel variants is perhaps not surprising given the large studies of type 2 diabetes performed and relative power, and the likelihood that any variant with a strong effect on first-phase insulin secretion is likely to have been associated with type 2 diabetes or an OGTT-based measure of insulin secretion. Previous family studies have also shown strong genetic overlaps between OGTT-derived CIR and IVGTT-derived AIR ([@B45]).

Known Type 2 Diabetes Risk Alleles Are Associated With Lower First-Phase Insulin Secretion in Response to Intravenous Glucose {#s27}
-----------------------------------------------------------------------------------------------------------------------------

We found that 21 of the alleles previously associated with higher type 2 diabetes risk are also associated with lower insulin secretion during IVGTT at *P* \< 0.05. Associations were similar with DI, which corrects for insulin sensitivity. Those with the strongest effects, and the only ones reaching genome-wide significance, were those in or near the *MTNR1B* and *CDKAL1* genes. In addition to classifications based on OGTT-derived measures ([@B2]), we can now also classify a number of previously unclassified loci as being involved in β-cell function. These include *IGF2BP2*, *C2CD4A*, *FAF1*, *PTPRD*, *AP3S2*, *NF1B*, *MAEA*, *KCNK16*, and *LPP*. Of the nine variants previously labeled as "β-cell" by Dimas et al. ([@B2]), eight were associated with first-phase insulin secretion, the exception being that in the *THADA* gene. On the basis of the analysis of Dimas et al., this variant is more likely to operate on fasting glucose rather than stimulated glucose tolerance.

A Common Allele Upstream of *PDX1* Is Associated With Higher Fasting Glucose and Lower First-Phase Insulin Secretion but Not Type 2 Diabetes {#s28}
--------------------------------------------------------------------------------------------------------------------------------------------

We identified six alleles that were associated with lower first-phase insulin secretion that were previously associated with higher fasting glucose levels but were not associated, at genome-wide significance, with type 2 diabetes risk. These include those in or near *PDX1*, *DNLZ*, *CRY2*, *GLIS3*, *PROX1*, and *ADRA2A* genes. Five of these six variants are nominally associated with type 2 diabetes risk in the expected direction. The exception is the allele ∼6.6 kb upstream of *PDX1,* a gene in which mutations cause maturity-onset diabetes of the young ([@B46]). This allele has the third strongest association with first-phase insulin secretion in our study, after those in *MTNR1B* and *CDKAL1*, and ahead of those in known type 2 diabetes loci, such as *TCF7L2*, *SLC30A8*, *IGF2BP2*, *CDKN2A/B*, and *HHEX/IDE*, but was not associated with type 2 diabetes in the most recent, multiethnic, type 2 diabetes study of 26,488 case and 83,964 control subjects. One explanation for this apparently paradoxical association is that the *PDX1* allele causes a stable resetting of glucose tolerance but does not lead to deterioration in β-cell function, as is seen in maturity-onset diabetes of the young 2. We also note that it is not associated with oral-based measures of insulin secretion ([@B3]).

Variants With Apparently Paradoxical Effects on Type 2 Diabetes Risk, Glycemic Traits, and First-Phase Insulin Secretion {#s29}
------------------------------------------------------------------------------------------------------------------------

We identified 16 variants with an apparently paradoxical effect on at least one measure of insulin secretion and type 2 diabetes risk---the type 2 diabetes risk allele was associated with higher insulin secretion. Many of these associations were much weaker when using DI rather than peak insulin response or AIR, suggesting the association with higher insulin secretion is a compensatory mechanism for higher background insulin resistance (*FTO*, *PPARG*) ([@B43]) or less efficient insulin processing (*MADD*, *ARAP1*, *PCSK1*) ([@B44]). The exceptions were the alleles in *GRB10* and *G6PC2*, where correcting for insulin resistance or using DI did not appreciably weaken the association. At both these loci, previous studies have noted the paradoxical associations between the allele associated with higher fasting glucose and higher OGTT-based insulin secretion ([@B3]). It was also previously shown that the effect of the *G6PC2* gene was dependent on glycemia, which may explain these apparent paradoxical results and suggests that effects of hyperglycemia may override genetic effects observed in healthy volunteers ([@B47]).

Known Type 2 Diabetes or Glycemic Trait Alleles Associated With Lower ISR {#s30}
-------------------------------------------------------------------------

For a subset of 1,268 individuals without diabetes, we had a measure of ISR by C-peptide deconvolution, a measure of insulin secretion that accounts for hepatic insulin clearance ([@B29],[@B30]). Eighteen known variants were nominally associated with ISR at *P* \< 0.05; 10 where the type 2 diabetes or glycemic trait risk allele was associated with lower ISR, and 8 where the risk allele was associated with higher ISR. These analyses highlighted 2 variants that had no clear underlying physiological profile based on previous data or our own peak insulin response or AIR analyses, those in *WFS1* and *TMPRSS6,* although one large study showed the *WFS1* allele as associated with oral-based measures of insulin secretion ([@B48]). The statistical confidence of these associations was not strong and further studies are needed to confirm them. The diabetes risk alleles associated with higher ISR are either likely to reflect the need for higher insulin secretion to remain without diabetes given a primary effect on insulin resistance (e.g., *HMGA2*) or insulin processing (e.g., *PCSK1*) or need further data to support the findings.

Alleles With Disproportionate Effects on Different Traits {#s31}
---------------------------------------------------------

We compared the effects of known variants across different traits ([Figs. 1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"}). Previous studies have highlighted that some known type 2 diabetes variants appear to have disproportionately small or large effects on type 2 diabetes risk compared with their effects on fasting glucose or insulin secretion ([@B2]). Here we highlight how measures of first-phase insulin secretion help refine these comparisons. Several variants are noteworthy. First, our most notable finding is that of the common variant 6 kb upstream of *PDX1*, which is the third most strongly associated locus with first-phase insulin secretion (peak insulin) but there is no evidence it affects type 2 diabetes risk even in the latest very large type 2 diabetes case-control study ([@B40]). Unlike the alleles in or near *G6PC2* and *GRB10*, the allele at *PDX1* associated with lower insulin secretion and was also associated with higher fasting glucose. Second, the common variant in *TCF7L2* appears to have a disproportionately small effect on first-phase insulin secretion in response to intravenous glucose given its effect on type 2 diabetes and in comparison with other variants. This observation is consistent with the effect of this variant on OGTT-based measures of insulin secretion ([@B2]). There is emerging evidence that *TCF7L2* influences diabetes risk through mechanisms involving multiple tissues ([@B49]--[@B52]), including a possible role on hepatic glucose production ([@B53]) in addition to direct effects at the pancreatic β-cell ([@B49],[@B52]). One possibility is that the *TCF7L2* risk allele also affects insulin clearance, a possibility consistent with our observation that the allele has a weaker effect on ISR (which uses C-peptide as the main measure of insulin secretion, and so excludes any effects on hepatic insulin clearance from the insulin secretion measure) than peak insulin response ([Figs. 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). Another possibility is that the effect of the *TCF7L2* risk allele on diabetes risk additionally depends on impaired incretin action ([@B54],[@B55]) and impaired proinsulin processing ([@B56],[@B57]), mechanisms not directly assessed in the current study. Third, our data are also consistent with previous data on OGTT-based measures that show the variant at *MTNR1B* has a disproportionately large effect on insulin secretion and fasting glucose levels compared with its effect on type 2 diabetes, possibly as a result of an additional effect on insulin action ([@B58]).

Strengths and Limitations {#s32}
-------------------------

Our study has several strengths and limitations. Although our sample size of ∼5,500 subjects is modest relative to previous OGTT-based measures, we have used the largest sample size yet for an intravenous-based measure of insulin secretion. Furthermore, we have characterized the most recent catalog of variants associated with type 2 diabetes and glycemic traits.

The limitations are that we had a mixed ancestry set of studies, although results in Europeans were very similar, suggesting that the known common variants have limited, if any, heterogeneous effects across different ethnic groups. Some of the associations we observed only reached nominal levels of statistical confidence, and further analyses are needed, ideally in even larger sample sizes, to characterize the approximately 50% of known variants with no clear mechanism.

Conclusions {#s33}
-----------

Our study provides further insight into the mechanisms by which common genetic variation influences type 2 diabetes risk and glycemic traits, and it further supports the notion that many established genetic variants for type 2 diabetes risk confer increased risk through an effect on β-cell function.
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###### Supplementary Tables

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1452/-/DC1>.
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